BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maduro JH, de Vries EG, Meersma G, Hougardy BM, van der Zee AG, de Jong S. Targeting Pro-Apoptotic TRAIL Receptors Sensitizes HeLa Cervical Cancer Cells to Irradiation-Induced Apoptosis. International Journal of Radiation Oncology*Biology*Physics 2008;72:543-52. [DOI: 10.1016/j.ijrobp.2008.06.1902] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Chandrasekaran AP, Poondla N, Ko NR, Oh SJ, Ramakrishna S. YM155 sensitizes HeLa cells to TRAIL-mediated apoptosis via cFLIP and survivin downregulation. Oncol Lett 2020;20:72. [PMID: 32863905 DOI: 10.3892/ol.2020.11933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zerp SF, Bibi Z, Verbrugge I, Voest EE, Verheij M. Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system. Clin Transl Radiat Oncol 2020;24:1-9. [PMID: 32577539 DOI: 10.1016/j.ctro.2020.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Lim B, Greer Y, Lipkowitz S, Takebe N. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers (Basel) 2019;11:E1087. [PMID: 31370269 DOI: 10.3390/cancers11081087] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
4 Shafabakhsh R, Reiter RJ, Mirzaei H, Teymoordash SN, Asemi Z. Melatonin: A new inhibitor agent for cervical cancer treatment. J Cell Physiol 2019;234:21670-82. [PMID: 31131897 DOI: 10.1002/jcp.28865] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 10.0] [Reference Citation Analysis]
5 Gamie Z, Kapriniotis K, Papanikolaou D, Haagensen E, Da Conceicao Ribeiro R, Dalgarno K, Krippner-Heidenreich A, Gerrand C, Tsiridis E, Rankin KS. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Cancer Lett 2017;409:66-80. [PMID: 28888998 DOI: 10.1016/j.canlet.2017.08.036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
6 Fan Y, Jiang Y, Liu J, Kang Y, Li R, Wang J. The anti-tumor activity and mechanism of alkaloids from Aconitum szechenyianum Gay. Bioorganic & Medicinal Chemistry Letters 2016;26:380-7. [DOI: 10.1016/j.bmcl.2015.12.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
7 Manzo-merino J, Contreras-paredes A, Vázquez-ulloa E, Rocha-zavaleta L, Fuentes-gonzalez AM, Lizano M. The Role of Signaling Pathways in Cervical Cancer and Molecular Therapeutic Targets. Archives of Medical Research 2014;45:525-39. [DOI: 10.1016/j.arcmed.2014.10.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
8 Wang XG, Jandl T, Dadachova E, Revskaya E. Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice. Ther Deliv 2014;5:139-47. [PMID: 24483193 DOI: 10.4155/tde.13.137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 Halim TA, Farooqi AA, Zaman F. Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes. Cancer Cell Int 2013;13:61. [PMID: 23773282 DOI: 10.1186/1475-2867-13-61] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
10 Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol 2012;2:169. [PMID: 23233905 DOI: 10.3389/fonc.2012.00169] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
11 Upreti M, Jamshidi-Parsian A, Apana S, Berridge M, Fologea DA, Koonce NA, Henry RL, Griffin RJ. Radiation-induced galectin-1 by endothelial cells: a promising molecular target for preferential drug delivery to the tumor vasculature. J Mol Med (Berl) 2013;91:497-506. [PMID: 23090010 DOI: 10.1007/s00109-012-0965-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
12 Gómez-Millán J, Katz IS, Farias Vde A, Linares-Fernández JL, López-Peñalver J, Ortiz-Ferrón G, Ruiz-Ruiz C, Oliver FJ, Ruiz de Almodóvar JM. The importance of bystander effects in radiation therapy in melanoma skin-cancer cells and umbilical-cord stromal stem cells. Radiother Oncol 2012;102:450-8. [PMID: 22169765 DOI: 10.1016/j.radonc.2011.11.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
13 Zhao J, Lu Y, Shen HM. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett 2012;314:8-23. [PMID: 22030255 DOI: 10.1016/j.canlet.2011.09.040] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
14 Bonner JA, Willey CD, Yang ES, Dobelbower MC, Sanford LL, Bright SJ, Buchsbaum DJ, Raisch KP. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation. Radiotherapy and Oncology 2011;101:183-9. [DOI: 10.1016/j.radonc.2011.05.083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
15 Niemoeller OM, Belka C. Radiotherapy and TRAIL for cancer therapy. Cancer Lett 2013;332:184-93. [PMID: 21824725 DOI: 10.1016/j.canlet.2011.07.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
16 Marini P, Budach W, Niyazi M, Junginger D, Stickl S, Jendrossek V, Belka C. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys 2009;75:198-202. [PMID: 19695436 DOI: 10.1016/j.ijrobp.2009.04.038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
17 Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, Hollema H, Mom CH, de Jong S, de Vries EG, de Bock GH, van der Zee AG. The Prognostic Value of TRAIL and its Death Receptors in Cervical Cancer. International Journal of Radiation Oncology*Biology*Physics 2009;75:203-11. [DOI: 10.1016/j.ijrobp.2009.03.071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]